SCII - Stem Cell Therapy International, Inc. Approved for OTC Bulletin Board and Commenced Trading on May 11, 2007 With Ticker Symbol "SCII"
May 14, 2007 9:37:00 AM
TAMPA, FL -- (MARKET WIRE) -- 05/14/07 -- Stem Cell Therapy International, Inc. (OTCBB: SCII), a leading stem cell research company operating international affiliate treatment clinics, announced today that its common stock has been approved for quotation on the National Association of Security Dealers (NASD) OTC Bulletin Board (OTCBB) commencing on May 11, 2007. The Company's ticker symbol is "SCII" and the Company's web site is www.SCTIcorp.com.
"Our listing on the OTCBB is a significant achievement for us," said Calvin Cao, president and CEO of Stem Cell Therapy International. "By being approved for quotation on the OTCBB we are executing our growth strategy to attract a wider range of investors in the U.S. and overseas. We are on a 'fast track' to revenue by keeping our focus on expanding our international treatment clinics, currently in three countries, to an additional seven countries. This is in accordance with our mission of creating the world's largest network of stem cell treatment facilities in conjunction with leading hospitals and cutting-edge medical professionals. Our unique business model of developing patented and patent pending stem cell solutions, in combination with our opening of affiliate treatment clinics worldwide, is what sets us apart from other stem cell companies that are limited to strictly research and development, but lacking a distribution network to generate revenues for their shareholders," stated CEO Calvin Cao.
"Stem cell transplantation therapy is a field of medicine which uses techniques and technologies that work by replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. Stem Cell Therapy International's proprietary treatments offer the dramatic health benefits of organ transplantation, while at the same time eliminating the need for major surgery, eliminating the time and pain associated with surgical recovery, eliminating the risk of organ transplant rejection, and providing a far less expensive solution than is currently available with traditional medical methods. These are just a few of the many reasons why stem cell treatments are thought to be the most promising development in medicine in the last 100 years. While many other stem cell companies have decided to postpone sales revenues until the FDA approves treatments for use in the USA, which could take several years, Stem Cell Therapy International has already begun to generate revenues in three countries where stem cell treatments are currently approved. To further increase our revenues while waiting for USA approvals we are in the process of expanding our clinics to another seven countries where stem cell treatments are already approved," stated Cao.
The validity and importance of stem cell treatment options has recently gained public and governmental support with the enactment of Proposition 71 in California, creating a fund of $3 billion for stem cell research, followed by funding appropriations in other states such as New Jersey, Massachusetts, Connecticut, Illinois and Wisconsin. Unlike many other stem cell companies whose business model is negatively impacted by a lack of federal funds for embryonic stem cell research, Stem Cell Therapy International is developing stem cell solutions based upon umbilical cord blood, which is not subject to the moral, legal and ethical controversy surrounding embryonic stem cell research.
About Stem Cell Therapy International
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company's website www.SCTIcorp.com
Forward-Looking Statements. This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.
For more information, please contact:
Stem Cell Therapy International, Inc.
Investor Relations
Calvin C. Cao
Chairman and CEO
T: 813-600-4088
E: calvin@SCTIcorp.com
New Clinic Partners, Licensing and Joint Ventures
Gerald R. Newman, Esq.
T: 310-652-6642
E: gnewman@mergerslawyer.com
News 
Market Data 
Discover 
